[HTML][HTML] Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous …
S Lonardi, AA Prete, F Morano, M Messina… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background No standard therapies beyond first line are established for advanced squamous
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal …
S Lonardi, AA Prete, F Morano, M Messina… - … for Immunotherapy of …, 2021 - europepmc.org
Background No standard therapies beyond first line are established for advanced squamous
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal …
S Lonardi, AA Prete, F Morano, M Messina… - JOURNAL FOR …, 2021 - research.unipd.it
Background No standard therapies beyond first line are established for advanced squamous
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal …
S Lonardi, AA Prete, F Morano… - Journal for …, 2021 - search.proquest.com
Background No standard therapies beyond first line are established for advanced squamous
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal …
S Lonardi, AA Prete, F Morano, M Messina… - JOURNAL FOR …, 2021 - arpi.unipi.it
Background No standard therapies beyond first line are established for advanced squamous
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal …
S Lonardi, AA Prete, F Morano, M Messina… - JOURNAL FOR …, 2021 - iris.unica.it
Background No standard therapies beyond first line are established for advanced squamous
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal …
S Lonardi, AA Prete, F Morano, M Messina… - JOURNAL FOR …, 2021 - air.unimi.it
Background No standard therapies beyond first line are established for advanced squamous
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
[HTML][HTML] Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous …
S Lonardi, AA Prete, F Morano, M Messina… - … for ImmunoTherapy of …, 2021 - jitc.bmj.com
Background No standard therapies beyond first line are established for advanced squamous
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal …
S Lonardi, AA Prete, F Morano… - Journal for …, 2021 - pubmed.ncbi.nlm.nih.gov
Background No standard therapies beyond first line are established for advanced squamous
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …
cell anal carcinoma (aSCAC). Earlier preliminary data suggest activity of epidermal growth …